SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 ( SSTR5 ) antagonist with IC 50 s of 9.6 and 57 nM for hSSTR5 and mSSTR5 , respectively.
Storage Temp
Store at -20°C
Shipped In
Ice chest + Ice pads
Product Description
SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 ( SSTR5 ) antagonist with IC 50 s of 9.6 and 57 nM for hSSTR5 and mSSTR5 , respectively
In Vitro
SSTR5 antagonist 1 (compound 25a) (30 μM) inhibits hERG activity by 5.6%. SSTR5 antagonist 1 (10 μM) shows highly selective inhibitory effect on SSTR5 over SSTR1-4, with inhibition rates of 11%, 8%, 14%, 10%. SSTR5 antagonist 1 (1 μM; 15 min and 30 min) exhibits good metabolic stability toward both human and mouse microsomes with in vitro CLint value of <10 μL/min/kg (HLM) and 19 μL/min/kg (MLM), respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SSTR5 antagonist 1 (compound 25a) (1 mg/kg; p.o.; single dose) is orally available with acceptable plasma exposure in mice in pharmacokinetic screening and exhibits excellent solubility (260 μg/mL, pH=6.8) . SSTR5 antagonist 1 (100 mg/kg; p.o.; single dose; measured at 0-120 min) augments insulin secretion in a glucose-dependent manner and lowers blood glucose concentration in high-fat diet fed C57BL/6J mice . SSTR5 antagonist 1 (1, 3, 10, and 30 mg/kg; p.o.; single dose) shows dose-dependent effect on glucose excursion measured during the oral glucose tolerance test in HFD fed C57BL/6J mice . Pharmacokinetic profiles in male ICR mouse (8-week-old) Route Dose (mg/kg) CL total (mL/h/kg) V ss (mL/kg) MRT (h) iv 0.1 1761 3052 1.7 / Route Dose (mg/kg) C max (ng/mL) T max (h) AUC 0-8 h (ng·h/mL) F (%) po 1 74.8 2.0 332 58 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: High-fat diet fed C57BL/6J mice Dosage: 100 mg/kg Administration: Oral gavage; single dose; monitored over 2 h Result: Showed the maximum efficacy superior to that of 10 mg/kg Glibenclamide (HY-15206) and comparable to that of 30 mg/kg Alogliptin (HY-A0023A). Augmented insulin secretion in a glucose-dependent manner and displayed a blood glucose-lowering effect, indicating its anti-diabetic efficacy in vivo.
